Anaptysbio paid its 3 named executives $10.5M in total in FY2025 (Jun). CEO Daniel Faga was paid $6.1M of that.
Pay$100 in the stock at the end of FY21 → $86
Pay of each named executive
Daniel FagaPresident and Chief Executive Officer and Director
| FY2025 (Jun) | ||||||
| FY2024 (Jun) | ||||||
| FY2023 (Jun) | ||||||
| FY2022 (Jun) |
4 years
Paul LizzulChief Medical Officer
| FY2025 (Jun) | ||||||
| FY2024 (Jun) | ||||||
| FY2023 (Jun) | ||||||
| FY2022 (Jun) |
4 years
Dennis MulroyChief Financial Officer
| FY2025 (Jun) | ||||||
| FY2024 (Jun) | ||||||
| FY2023 (Jun) |
3 years
CEO pay against the pay peers
In FY2025 (Jun), the median CEO pay of the 2 peers with pay on file was $6.6M. The CEO of Anaptysbio was paid $6.1M, 8% below the median.
- 1Kymera Therapeutics
- 2AnaptysbioThis company
- 3Kura Oncology
- 4ALX OncologyNot disclosed
- 5Allogene TherapeuticsNot disclosed
- 6Apogee TherapeuticsNot disclosed
- 7ArcellxNot disclosed
- 8Astria TherapeuticsNot disclosed
- 9Centessa PharmaceuticalsNot disclosed
- 10IGM BiosciencesNot disclosed
- 11Janux TherapeuticsNot disclosed
- 12Jasper TherapeuticsNot disclosed
- 13Pilant TherapeuticsNot disclosed
- 14Replimune GroupNot disclosed
- 15XencorNot disclosed
- 16iTeos TherapeuticsNot disclosed
Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.